Associations of high-risk drug patterns with mortality among community-dwelling older adults: A 23-year prospective cohort study

Abstract

Background Data on drug safety in multimorbid older-adults are limited, as clinical trials often apply upper age limits and focus on individual drugs or specific combinations. We aimed to explore high-risk drug patterns in community-dwelling older-adults, and their associations with long-term mortality. Methods We included 1,048 participants from a longitudinal population-based cohort, all taking at least one medication. Participants were examined in 1999–2007 and followed for mortality through March 2022. Individuals with similar profiles of high-risk drugs, identified using Beers criteria as potentially inappropriate for most older adults or requiring caution, were grouped using agglomerative hierarchical clustering. Cox and competing-risk regressions were used to examine the associations of the high-risk drug patterns with all-cause and non-cancer mortality. Results The most prevalent morbidities among participants (mean age 73.3 ± 7.3 years, 55.9% women) were hypertension (55.3%) and cardiovascular diseases (45.5%), and 77.7% took at least one high-risk drug. Five distinct patterns were identified: ‘None’ cluster (no dominant high-risk drug); ‘Calcium channel blockers’ (CCBs) cluster, with high nonsteroidal anti-inflammatory drug (NSAID) prevalence; ‘Renin-angiotensin-aldosterone system (RAAS) inhibitors’ cluster, with a high concomitant use of sulfonylureas compared to other clusters; ’Diuretics’ cluster, with a relatively high prevalence of antithrombotics and proton pump inhibitors; and ’Benzodiazepines’ cluster, with a relatively high antidepressant prevalence. Clusters differed by age, sex, ethnicity, and health characteristics. In multivariable analysis, the ‘Diuretics’ cluster was associated with increased all-cause (HR = 1.33, 95%CI: 1.03–1.72) and non-cancer (HR = 1.41, 95%CI: 1.03–1.93) mortality compared to the ‘None’ cluster. The ‘CCBs’ cluster was associated with a greater risk for non-cancer mortality. Several drug combinations were identified as potential contributors to the increased risk observed in these clusters, including the concomitant use of NSAIDs and antihypertensives and a possible CCB-diuretic prescribing cascade. Conclusions Examining high-risk drug patterns offers a patient-centered approach to improving evidence-based medication guidelines and facilitating early interventions for vulnerable older-adults.